Tidal Investments LLC Has $1.80 Million Stock Position in Solventum Co. (NYSE:SOLV)

Tidal Investments LLC reduced its position in shares of Solventum Co. (NYSE:SOLV) by 15.2% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 25,823 shares of the company’s stock after selling 4,614 shares during the quarter. Tidal Investments LLC’s holdings in Solventum were worth $1,800,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in SOLV. Envestnet Portfolio Solutions Inc. bought a new stake in Solventum during the 2nd quarter worth about $491,000. Assenagon Asset Management S.A. bought a new stake in Solventum during the 2nd quarter worth about $347,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in Solventum during the 2nd quarter worth about $24,533,000. Raymond James & Associates bought a new stake in Solventum during the 2nd quarter worth about $16,986,000. Finally, Nisa Investment Advisors LLC bought a new stake in Solventum during the 2nd quarter worth about $2,147,000.

Solventum Price Performance

NYSE SOLV opened at $68.60 on Wednesday. The business has a 50 day simple moving average of $71.00 and a 200 day simple moving average of $63.38. Solventum Co. has a 52-week low of $47.16 and a 52-week high of $96.05. The company has a debt-to-equity ratio of 2.45, a current ratio of 1.15 and a quick ratio of 0.83.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Morgan Stanley boosted their price objective on Solventum from $60.00 to $73.00 and gave the stock an “equal weight” rating in a report on Monday, November 11th. Piper Sandler upped their price target on Solventum from $71.00 to $75.00 and gave the company a “neutral” rating in a research note on Friday, November 8th. Mizuho initiated coverage on Solventum in a research note on Wednesday, December 4th. They issued a “neutral” rating and a $70.00 price target for the company. Stifel Nicolaus initiated coverage on Solventum in a research note on Tuesday, October 8th. They issued a “buy” rating and a $82.00 price target for the company. Finally, Wolfe Research initiated coverage on Solventum in a research note on Thursday, September 26th. They issued a “peer perform” rating for the company. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and one has assigned a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $68.29.

About Solventum

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration.